To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (LGS) who are refractory to antiseizure medications. The intent is to determine the feasibility and the optimal design of a subsequent pivotal study in order to expand the indication for use for the RNS System as a treatment for patients with medically intractable LGS.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety: Annual device-related serious adverse event (SADE) rate
Timeframe: 12 months post-implant
Safety: Annual device-related serious adverse event (SADE) rate
Timeframe: 24 months post-implant
Effectiveness: Blinded evaluation period (BEP) responder rate
Timeframe: 12 months post-implant